Zentalis Pharmaceuticals (ZNTL) has filed a preliminary prospectus for a $100M IPO.
The New York City-based biopharmaceutical firm
develops small molecule cancer therapies based on its Integrated
Discovery Engine. Lead candidate is ZN-c5,
an oral selective estrogen receptor degrader (SERD) in Phase 1/2
development for ER+/HER2- advanced/metastatic breast cancer. Topline
data from the first phase should be available in H2. Other pipeline
candidates include Phase 1/2-stage ZN-c3 for solid tumors and Phase
1/2-stage ZN-e4 for non-small cell lung cancer (NSCLC).
2019 Financials: Operating Expenses: $46.8M (+97%); Net Loss: ($45.7M) (-117%); Cash Burn: ($39.1M) (-61%).
https://seekingalpha.com/news/3549545-zentalis-pharmaceuticals-readies-ipo
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.